Filing Flows

Filing Flows › Coya Therapeutics (COYA) › Next earnings date

Coya Therapeutics (COYA) earnings on Nov 11, 2026: what to expect

Coya Therapeutics (COYA) is expected to report earnings on Nov 11, 2026 (estimated), in 3 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.35 (−$0.37 to −$0.33, 3 estimates) on revenue of $79K, against −$0.13 and $3.6M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.

Report dateNov 11, 2026 (estimated)
Days to go3
EPS estimate−$0.35
Revenue estimate$79K
Beat rate75%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Coya Therapeutics: revenue lines, growth year over year, Q2 2026Coya Therapeutics: revenue lines, growth year over year, Q2 2026Revenue+49%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.13 on revenue of $4.5M, against the analysts' −$0.35.

The last report

Coya Therapeutics reported revenue of $244K for the second quarter 2026 (+49% Y/Y), net loss $6.6M. How it makes money → · Every quarter →

Coya Therapeutics: EPS against the estimate, last 4 reportsCoya Therapeutics: EPS against the estimate, last 4 reportsEstimateReported−$0.30−$0.13Nov 25−$0.30−$0.34Mar 26−$0.39−$0.32May 26−$0.36−$0.28Aug 26
Latest (Aug 26): Estimate −$0.36, Reported −$0.28.

Coya Therapeutics' latest quarter

Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year), net loss $6.6M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does COYA report earnings?

Coya Therapeutics is expected to report on Nov 11, 2026 (estimated).

What are analysts expecting from Coya Therapeutics?

EPS of −$0.35 and revenue of $79K for the quarter.

Does Coya Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.